Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2006 2
2007 3
2008 7
2009 2
2010 1
2011 3
2012 2
2014 3
2015 2
2016 3
2017 2
2018 5
2019 1
2020 4
2021 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion.
Flores AJ, Bartlett MJ, Seaton BT, Samtani G, Sexauer MR, Weintraub NC, Siegenthaler JR, Lu D, Heien ML, Porreca F, Sherman SJ, Falk T. Flores AJ, et al. Among authors: sherman sj. bioRxiv [Preprint]. 2023 Sep 26:2023.07.31.551112. doi: 10.1101/2023.07.31.551112. bioRxiv. 2023. PMID: 37577558 Free PMC article. Updated. Preprint.
Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia.
Bartlett MJ, Flores AJ, Ye T, Smidt SI, Dollish HK, Stancati JA, Farrell DC, Parent KL, Doyle KP, Besselsen DG, Heien ML, Cowen SL, Steece-Collier K, Sherman SJ, Falk T. Bartlett MJ, et al. Among authors: sherman sj. Exp Neurol. 2020 Nov;333:113413. doi: 10.1016/j.expneurol.2020.113413. Epub 2020 Jul 25. Exp Neurol. 2020. PMID: 32717354 Free PMC article.
The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia.
Flores AJ, Bartlett MJ, Root BK, Parent KL, Heien ML, Porreca F, Polt R, Sherman SJ, Falk T. Flores AJ, et al. Among authors: sherman sj. Neuropharmacology. 2018 Oct;141:260-271. doi: 10.1016/j.neuropharm.2018.09.005. Epub 2018 Sep 7. Neuropharmacology. 2018. PMID: 30201210 Free PMC article.
41 results